Enterprise Value
25.49M
Cash
7.118M
Avg Qtr Burn
-5.923M
Short % of Float
1.91%
Insider Ownership
32.74%
Institutional Own.
1.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EVX-01 + pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Bladder cancer, Melanoma | Phase 2 Update | |
EVX-02 Details Melanoma | Phase 1/2 Update |